Pardoprunox

Pardoprunox is an investigational drug that was under development by Solvay Pharmaceuticals. It is a dopamine agonist and 5-HT1A receptor agonist that was being investigated for use in the treatment of Parkinson's disease and restless legs syndrome. However, development was discontinued in 2011.

Pharmacology

Pardoprunox has a unique pharmacological profile, acting as a partial agonist at both D2 and 5-HT1A receptors. It also has affinity for D3, D4, and 5-HT2B receptors, though its effects at these sites are less well understood.

Clinical trials

Pardoprunox has undergone Phase II and Phase III trials for Parkinson's disease and restless legs syndrome. However, in 2011, Solvay Pharmaceuticals announced that they were discontinuing development of the drug due to unsatisfactory results.

See also

• Dopamine agonist
• 5-HT1A receptor
• Parkinson's disease
• Restless legs syndrome

References

Pardoprunox Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski